CONMED Corporation (CNMD) EVP Sells $1,488,704.10 in Stock
CONMED Corporation (NASDAQ:CNMD) EVP Luke A. Pomilio sold 29,363 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $50.70, for a total transaction of $1,488,704.10. Following the sale, the executive vice president now directly owns 45,486 shares of the company’s stock, valued at approximately $2,306,140.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
CONMED Corporation (NASDAQ CNMD) opened at $49.79 on Friday. The firm has a market cap of $1,390.83, a price-to-earnings ratio of 28.45, a P/E/G ratio of 3.14 and a beta of 0.66. The company has a quick ratio of 1.49, a current ratio of 2.56 and a debt-to-equity ratio of 0.84. CONMED Corporation has a 1-year low of $39.74 and a 1-year high of $54.47.
CONMED Corporation (NASDAQ:CNMD) last issued its earnings results on Thursday, November 2nd. The medical technology company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.01. The company had revenue of $190.10 million during the quarter, compared to the consensus estimate of $187.13 million. CONMED Corporation had a net margin of 1.99% and a return on equity of 8.40%. CONMED Corporation’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.41 EPS. analysts expect that CONMED Corporation will post 1.87 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/11/12/conmed-corporation-cnmd-evp-sells-1488704-10-in-stock.html.
A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in CONMED Corporation by 46,036.5% in the 1st quarter. BlackRock Inc. now owns 3,153,427 shares of the medical technology company’s stock worth $140,043,000 after buying an additional 3,146,592 shares during the period. Vanguard Group Inc. boosted its holdings in shares of CONMED Corporation by 1.1% during the 2nd quarter. Vanguard Group Inc. now owns 2,294,366 shares of the medical technology company’s stock valued at $116,875,000 after purchasing an additional 25,484 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of CONMED Corporation by 5.4% during the 3rd quarter. Victory Capital Management Inc. now owns 2,180,586 shares of the medical technology company’s stock valued at $114,415,000 after purchasing an additional 111,096 shares during the last quarter. Cramer Rosenthal Mcglynn LLC boosted its holdings in shares of CONMED Corporation by 7.6% during the 2nd quarter. Cramer Rosenthal Mcglynn LLC now owns 1,067,844 shares of the medical technology company’s stock valued at $54,396,000 after purchasing an additional 75,055 shares during the last quarter. Finally, Macquarie Group Ltd. boosted its holdings in shares of CONMED Corporation by 13.9% during the 3rd quarter. Macquarie Group Ltd. now owns 731,957 shares of the medical technology company’s stock valued at $38,406,000 after purchasing an additional 89,078 shares during the last quarter. 98.75% of the stock is owned by institutional investors.
A number of brokerages have recently issued reports on CNMD. Zacks Investment Research downgraded shares of CONMED Corporation from a “hold” rating to a “sell” rating in a research report on Monday, November 6th. BidaskClub downgraded shares of CONMED Corporation from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $46.00 target price on shares of CONMED Corporation in a report on Friday, November 3rd. KeyCorp reaffirmed a “hold” rating on shares of CONMED Corporation in a report on Friday, November 3rd. Finally, TheStreet raised shares of CONMED Corporation from a “c+” rating to a “b-” rating in a report on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $50.33.
CONMED Corporation Company Profile
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
Receive News & Stock Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related stocks with our FREE daily email newsletter.